"We thought there might be a preventive effect towards the development from CHIP to CCUS to MDS, so it’s a sort of a continuum," said Kirsten Grønbæk, MD, PhD.
|Videos|June 11, 2019
Dr. Daniel George on the Treatment Landscape for RCC
Author(s)Daniel George, MD
Cancer Network spoke with Daniel George, MD, of Duke Health, about the treatment landscape and current trials for renal cell carcinoma.
Advertisement
Cancer Network spoke with Daniel George, MD, of Duke Health, about the treatment landscape and current trials for renal cell carcinoma.
Advertisement
Related to this article
Ralph V. Boccia, MD, FACP, discussed how time since CAR T-cell therapy and toxicity profiles guide bispecific selection in relapsed multiple myeloma.
Al-Ola A. Abdallah, MD, explains a possible biological reason IMiD holding therapy benefited ide-cel but not cilta-cel recipients.
Industry payments to oncologists were associated with greater use of the promoted treatment, whether or not it was guideline-preferred for the patient’s cancer.
The phase 2/3 AHEAD-MERIT trial will continue to assess overall survival among patients who received BNT113 plus pembrolizumab for head and neck cancer.
Ralph V. Boccia, MD, FACP, discusses payer models, prior authorization, cost recovery, and patient assistance for bispecifics like teclistamab/daratumumab.
Robot-assisted radical hysterectomy reduced mostly low-grade intraoperative complications vs open surgery in early-stage cervical cancer.
Ralph V. Boccia, MD, FACP, explained why CAR T-cell therapy followed by bispecific antibodies may be the preferred sequence at first relapse in multiple myeloma.
Advertisement
Advertisement
Trending on CancerNetwork
1
BNT113/Pembrolizumab Misses PFS End Point in HPV16+ Head and Neck Cancer
2
RYZ101 Improves Progression-Free Survival in Previously Treated GEP-NETs
3
Why CAR T-Cell Therapy Before Bispecifics May Be the Ideal Multiple Myeloma Sequence
4
Teclistamab Vs Talquetamab After Relapse on CAR T-Cell Therapy in Multiple Myeloma
5